Artgen

Artgen is a Russian biotechnology company. It was founded in 2003. It is engaged in scientific research, development of innovative drugs and high-tech services in the field of regenerative medicine, medical genetics, gene therapy, bioinsurance and biopharmaceuticals. It independently promotes his own developments in the market.
Artgen stock price chart
+124%
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Artgen balance sheet

Report period2018 2019 2020 2021 2022 Q2 23
End date of the reporting period
Capitalization, ₽
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Artgen cash flows

Report period2018 2019 2020 2021 2022 Q2 23 TTM
End date of the reporting period
Sales
Operation Income
Earnings
Shareholders earnings
EBITDA
OIBDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Artgen multipliers

Report period2018 2019 2020 2021 2022 Q2 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/OIBDA
EV/EBITDA
EV/OIBDA

Artgen profitability

Report period2018 2019 2020 2021 2022 Q2 23 TTM
ROA
ROE
ROS
EBITDA Margin
Operating margin
Artgen assets
Artgen cash flows
Artgen dividends
0.91%

Artgen dividend policy

The recommended amount of dividend payments is determined based on year-end financial results, economic situation, and industry position and may range from 40% to 60% of net profit.

Artgen shares

TickerNameTypeNominal valueISINPrice
ABIO:RMArtgenCommon shareRUB 0.1RU000A0JNAB6RUB 118.1

Artgen bonds

Share capital structure of Artgen
Artgen news
07.09.2023
Companies of Artgen Biotech Group are considering entering the markets of a number of friendly countries, Artgen Biotech Chairman of the Board of Directors Artur Isayev said. First to enter foreign markets is likely to be Genetico, which is currently negotiating with potential partners in Kazakhstan and the United Arab Emirates.
Source: {source} pictogram finam.ru
Pictogram next
30.08.2023
Artgen's IFRS net profit for 6 months of 2023 amounted to ₽36,068 million, up 20.5% from ₽29,925 million in the previous year. Revenue increased 19.5% to ₽621.12 million compared to ₽519.89 million a year earlier.
Source: {source} pictogram e-disclosure.ru
Pictogram next
04.08.2023
Artgen's stock ticker will change from ISKJ to ABIO effective August 18.
Source: {source} pictogram moex.com
Pictogram next
01.08.2023
Artgen's RAS net profit for 6 months of 2023 amounted to ₽29.596 million, down 3 times from ₽99.43 million in the previous year. Revenue fell 24.4% to ₽32.8 million against ₽43.412 million a year earlier.
Source: {source} pictogram e-disclosure.ru
Pictogram next
All Artgen news
General information
Company nameArtgen
Tags#biotechnology, #pharmacy, #innovations of the russia
SectorHealth Care / Health Care Equipment & Services / Health Care Providers & Services / Health Care Services
Business addressRF, g. Moskva
Mailing address117036, g. Moskva, prospekt 60-letiya Oktyabrya, d. 10A, etazh 3, pom. 24
CEOMasyuk Sergey Vladimirovich
Phone+7 (495) 646-80-76
Websiteartgen.ru
Information disclosuree-disclosure.ru